Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient…
An institutional-grade, numbers-driven thesis on ACRV — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of July 4, 2026, TradersQuant's model rates Acrivon Therapeutics, Inc. Common Stock (ACRV) 65/100 with a 12-month base-case forecast of $21.83 — +1169.2% versus the current price of $1.72. Acrivon Therapeutics, Inc. Common Stock trades at $1.72 in the Healthcare sector, with a market capitalisation of $54.3M. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for ACRV is $21.83, implying +1169.2% versus the current price. The model's 12-month scenario range runs from $1.18 (bear) to $2.35 (bull), with a base case of $1.63.
On the fundamentals, Acrivon Therapeutics, Inc. Common Stock shows a P/E of -0.9, trailing revenue of $0, revenue growth of +0.0% YoY. This page also tracks ACRV's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
ACRV currently carries a TradersQuant composite score of 65/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $21.83 implies +1169.2% from $1.72. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for ACRV is $21.83, about +1169.2% versus the latest price of $1.72. Consensus is based on 10 analysts.
TradersQuant's 12-month model forecast for ACRV is a base case of $1.63, ranging from $1.18 (bear) to $2.35 (bull), an expected return of -5.0%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for ACRV over the next 12 months is $1.63 in the base case (bear $1.18, bull $2.35), versus today's price of $1.72. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for ACRV — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates ACRV's fair value at $21.83, implying +1169.2% of expected upside versus the current price.
Acrivon Therapeutics, Inc. Common Stock does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
